|1.||André, Sabine: 4 articles (06/2012 - 03/2005)|
|2.||Gabius, Hans-Joachim: 4 articles (06/2012 - 03/2005)|
|3.||André, S: 3 articles (07/2015 - 02/2001)|
|4.||Kopitz, Jürgen: 3 articles (06/2012 - 12/2005)|
|5.||Kaltner, Herbert: 3 articles (04/2012 - 03/2005)|
|6.||Ledeen, Robert W: 2 articles (10/2012 - 04/2012)|
|7.||Wu, Gusheng: 2 articles (10/2012 - 04/2012)|
|8.||Girolami, Francesca: 2 articles (08/2012 - 07/2012)|
|9.||Galassi, Giuliana: 2 articles (08/2012 - 07/2012)|
|10.||Yuki, Nobuhiro: 2 articles (01/2012 - 08/2004)|
01/01/1991 - "Is ganglioside GM1 effective in the treatment of stroke?"
01/01/1991 - "Nine double-blind, placebo-controlled clinical trials involving 784 patients with nonhaemorrhagic stroke have been reviewed to investigate the clinical efficacy of ganglioside GM1 in this disorder. "
06/01/1994 - "We sought to assess the safety and efficacy of ganglioside GM1 in acute (< or = 48 hours), anterior circulation ischemic stroke. "
05/01/1989 - "Trial of ganglioside GM1 in acute stroke."
09/01/1988 - "Trial of ganglioside GM1 in acute stroke."
08/01/1993 - "These studies support the hypothesis that, ischemia leads to a irreversible plasma membrane disorganization which underlies the eventual cell death, and protection and restoration of these membrane changes by drugs, such as ganglioside GM1 leads to neuroprotection against ischemic injury."
02/01/1994 - "Six were given 30 mg/kg ganglioside GM1 through the umbilical vein, commencing immediately after the release of the occluder, over the next 2 hours, followed by a continuous infusion of 30 mg/kg/day over 60 hours after ischemia; these were compared with seven vehicle-treated controls. "
01/01/1994 - "30 min before ischemia, or the ganglioside GM1, 30 mg/kg, was given i.p. "
11/01/1986 - "Effect of the ganglioside GM1, on cerebral metabolism, microcirculation, recovery kinetics of ECoG and histology, during the recovery period following focal ischemia in cats."
01/01/1987 - "We report here that ganglioside (GM1 or AGF2) treatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils by permanent unilateral ligation of the common carotid artery. "
|3.||Parkinson Disease (Parkinson's Disease)
10/01/2012 - "Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans."
12/01/1992 - "Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease."
07/01/2000 - "We investigated whether the ganglioside GM1 or the lazaroid tirilazad mesylate (U-74006F) could improve survival of grafts derived from cryopreserved VM in a rat model of Parkinson's disease. "
|4.||Brain Ischemia (Cerebral Ischemia)
10/01/1998 - "The ganglioside GM1 has been shown to be effective in the treatment of experimental cerebral ischemia. "
07/16/2010 - "Monosialotetrahexosy-1 ganglioside (GM1) has been shown to reduce brain damage induced by cerebral ischemia. "
06/01/1989 - "The effect of the ganglioside GM1 was studied in a focal cerebral ischemia model in 30 cats consisting of 2 hours of middle cerebral artery occlusion followed by 4 hours of recirculation. "
02/01/1994 - "These results showed that ganglioside GM1 treatment initiated immediately after a transient hypoxic-ischemic episode stabilized membrane function and markedly improved neuronal outcome after subsequent insults, suggesting its potential therapeutic value in acute situations of repeated hypoxia-ischemia in the perinatal period."
01/01/2013 - "Taken together, our findings suggested that ganglioside GM1 treatment reduces hypoxia-ischemia induced impairment of the neurobehavioral function in WMD in neonatal rats. "
|4.||L-Type Calcium Channels (Dihydropyridine Receptor)
|7.||Biological Markers (Surrogate Marker)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||Staphylococcal Protein A (A, Protein)
|10.||Methylprednisolone Hemisuccinate (A-MethaPred)